BOSTON, April 20, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company
focused on new immunotherapies, today announced that it will present updated results from its Phase 1, multicenter, dose-escalation
study of Ad-RTS-hIL-12 + orally administered veledimex in patients with recurrent or progressive glioblastoma at the 2017 American
Society of Clinical Oncology (ASCO) Annual Meeting to be held June 2-6 in Chicago. Ad-RTS-hIL-12 + veledimex is a novel, viral gene
therapy candidate for the controlled expression of interleukin-12 (IL-12), a pro-inflammatory cytokine critical for stimulating
anti-cancer immune responses.
Details for the poster presentation at ASCO 2017:
Title: Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability
and survival in recurrent glioblastoma
Abstract Number: 2044
Session: Central Nervous System Tumors
Date and Time: Monday, June 5, 2017, 1:15 – 4:45 p.m. CT
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression,
control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer
and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and
the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use
non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together
with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely
modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based
therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
Forward-Looking Safe-Harbor Statement:
This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended
to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995,
as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms
such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." All of such statements are subject to certain
risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause
actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk factors contained in our periodic and interim reports filed with the
Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December
31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date
hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
Trademarks
RheoSwitch Therapeutic System® and RTS® are registered trademarks of Intrexon Corporation.
Contact: Amy Trevvett Vice President, Corporate Communications and Investor Relations 617-502-1881 atrevvett@ziopharm.com David Pitts Argot Partners 212-600-1902 david@argotpartners.com
